A retrospective drug utilization evaluation of antihyperlipidaemic agents in a medical centre in Taiwan

Journal of Clinical Pharmacy and Therapeutics

Volumn 22, Issue 4, 1997, Pages 291-299

  Yang, Y H K ^a,c   Kao, S M ^a   Chan, K W A ^b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NONE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; MEVINOLIN; PRAVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; DRUG UTILIZATION; EUROPE; FEMALE; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NORTH AMERICA; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN;

EID: 0031406998     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1997.10575105.x     Document Type: Article

References (23)

1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Journal of the American Medical Association, 269, 3015-3023.
2. Heiss C, Johnson NJ, Reiland S, Davis CE, Tyroler HA. (1980) The epidemiology of plasma high density lipoprotein cholesterol levels. Lipid Research Clinics Program Prevalence Study. Circulation, 62 (Suppl. 4), 116-136.
3. Lipid Research Clinics Program. (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association, 251, 351-364.
4. Lipid Research Clinics Program. (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Journal of the American Medical Association, 251, 365-374.
5. Steinberg D. et al. (1985) Consensus Conference. Lowering blood cholesterol to prevent heart disease. National Institutes of Health, Bethesda, MD. Journal of the American Medical Association, 253, 2080-2086.
6. The Expert Panel. (1988) Report of The National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Archives of Internal Medicine, 148, 36-69.
7. Gordon DJ, Probstfield JL, Garrison RJ, et al. (1989) High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79(1), 8-15.
8. Frick MH, Elo O, Haapa K, at al. (1987) Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine, 317(20), 1237-1245.
9. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. (1987) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Journal of the American Medical Association, 257(23), 3233-3240.
10. Study Group, European Atherosclerosis Society. (1987) Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. European Heart Journal, 8, 77-88.
11. Davey-Smith G, Pekkanen J. (1992) Should there be a moratorium on the use of cholesterol lowering drugs? British Medical Journal, 304, 431-433.
12. Betteridge DJ, Sodson PM, Durrington PN, et al. (1993) Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgraduate Medicine Journal, 69(811), 359-369.
13. Canadian consensus conference cholesterol: final report. (1988) Canadian consensus conference on the prevention of heart and valvular disease by altering serum cholesterol and lipoprotein risk factors. Canadian Medical Association Journal, 139(Suppl. 11), 1-8.
14. Canadian task force on the periodic health examination. (1993) Periodic health examination, 1993 update: 2. Lowering the blood total cholesterol level to prevent coronary heart disease. Canadian Medical Association Journal, 148, 521-538.
15. Canadian lipoprotein conference ad hoc committee on guidelines for dyslipoproteinemias. (1990) Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Medical Association Journal, 142, 1371-1382.
16. Robert K, Susan S, John O, et al. (1989) Criteria for drug use evaluation: lovastatin (inpatients and outpatients). American Society of Hospital Pharmacists, 1, 95-99.
17. Paula S. (1990) Criteria for drug use evaluation: gemfibrozil (adult inpatients and outpatients). American Society of Hospital Pharmacists, 2, 59-64.
18. Friedwald WT, Levy RI, Fredrickson DS. (1972) Estimation of concentration of low density lipoprotein cholesterol on plasma without use of the ultracentrifuge. Clinical Chemistry, 18, 449-502.
19. Todd PA, Ward A. (1988) Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs, 36, 314-339.
20. McKenney JM. (1988) Lovastatin: a new cholesterol lowering agent. Clinical Pharmacy, 7, 21-36.
21. Hunninghake DB, Knopp RH, Schonfeld G, et al. (1990) Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis, 85(1), 81-89.
22. Magarian GJ, Lucas LM, Colley C. (1991) Gemfibrozil-induced myopathy. Archives of Internal Medicine, 151, 1873-1874.
23. Larsen ML, Illingworth DR. (1994) Drug treatment of dyslipoproteinemia. Lipids, 78(1), 225-245.